Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Study Location:

Find another location


Questions to ask
Skip to Main Content

Keep up to date

Sign up for news and information about taking part and shaping research.

English | Cymraeg
Be Part of Research - Trial Details - A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis
Back

A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis

Not Recruiting

Open to: ALL

Age: 18.0 - N/A

Belfast Cardiff Cambridge Manchester Headington London London Glasgow

Medical Conditions

Leukemia
Neoplasms
Preleukemia
Precancerous Conditions
Neoplasms by Histologic Type
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Myelodysplastic Syndromes
Primary Myelofibrosis
Myeloproliferative Disorders
Myelodysplastic-Myeloproliferative Diseases
Hematologic Diseases
Bone Marrow Diseases
Thrombocytosis
Thrombocythemia, Essential

This information is provided directly by researchers and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information.


Phase 1 Part (Complete): Open-label, sequential dose escalation study of pelabresib in patients with previously treated Acute Leukemia, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasms, and Myelofibrosis.

Phase 2 Part: Open-label study of CPI-0610 with and without Ruxolitinib in patients with Myelofibrosis.

CPI-0610 is a small molecule inhibitor of bromodomain and extra-terminal (BET) proteins.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Jul 2014 Oct 2024

Publications

"Zavidij O, Haradhvala NJ, Meyer R, Cui J, Verstovsek S, Oh S, Mead A, Taverna P. MPN-238 Single-Cell RNA Profiling of Myelofibrosis Patients Reveals Pelabresib-Induced Decrease of Megakaryocytic Progenitors and Normalization of CD4+ T Cells in Peripheral Blood. Clin Lymphoma Myeloma Leuk. 2022 Oct;22 Suppl 2:S331-S332. doi: 10.1016/S2152-2650(22)01448-3."; "36163997"

INTERVENTIONAL

Intervention Type : DRUG
Intervention Arm Group : Arm 1: Prior JAKi (JAK inhibitor) Monotherapy Arm (MF patients treated with pelabresib alone);Arm 2: Prior JAKi Combination Arm;Arm 3: JAKi NaĂŻve Combination Arm;Arm 4: Essential Thrombocythemia (ET) Monotherapy Arm;

Intervention Type : DRUG
Intervention Arm Group : Arm 2: Prior JAKi Combination Arm;Arm 3: JAKi NaĂŻve Combination Arm;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • Belfast City Hospital
    Belfast
    BT9 7AB
  • University Hospital of Wales
    Cardiff
    CF14 4XW
  • University of Cambridge
    Cambridge
    CB2 0QQ
  • The Christie Hospital
    Manchester
    M20 4BX
  • Oxford University Hospitals
    Headington
    Oxford
    OX3 7LE
  • University College London Hospital's NHS foundation Trust
    London
    NW1 2PG
  • Guys and St Thomas' Hospital - Haematology
    London
    SE1 9RT
  • Beatson West of Scotland Cancer Centre
    Glasgow
    G12 0YN


The study is sponsored by Constellation Pharmaceuticals and is in collaboration with The Leukemia and Lymphoma Society.



We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: NCT02158858
Last updated 05 March 2024

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top